Cancer's Sneaky Survival Trick: How It Turns Cell Death into a Comeback Story
Imagine a scenario where the very process meant to destroy cancer ends up fueling its resurgence. This is the startling discovery that has the scientific community buzzing. As of November 19, 2025, researchers at the University of California San Diego have uncovered a baffling mechanism: cancer cells are hijacking a protein typically activated during cell death to not only survive treatment but also regrow stronger. But here's where it gets controversial—could this mean we’ve been approaching cancer treatment all wrong?
Cancer remains a leading cause of death globally, with one in six fatalities attributed to the disease. While initial treatments often show promise, the development of drug resistance is a persistent nightmare. Traditionally, this resistance has been linked to genetic mutations that evolve over time, much like bacteria becoming resistant to antibiotics. However, this new research flips the script by focusing on a non-genetic mechanism that kicks in much earlier—and it’s a game-changer.
‘This completely rewrites our understanding of how cancer cells evade death,’ said Matthew J. Hangauer, Ph.D., assistant professor of dermatology at UC San Diego School of Medicine and a member of the Moores Cancer Center. ‘Instead of killing the cell, the sublethal signals from this process actually help cancer regrow. By blocking these signals, we might prevent tumors from bouncing back during treatment.’
The study, published in Nature Cell Biology, reveals that in models of melanoma, lung, and breast cancers, a subset of ‘persister’ cells survives treatment by chronically activating a protein called DNA fragmentation factor B (DFFB). This activation is too weak to kill the cells but strong enough to disrupt growth-suppressing signals, allowing the cancer to regrow. The kicker? DFFB is nonessential in healthy cells but critical for these persister cells, making it a prime target for new therapies.
And this is the part most people miss: While most research on drug resistance focuses on genetic mutations, this study highlights a non-genetic mechanism that acts much earlier in the process. ‘This opens the door to entirely new treatment strategies,’ explained August F. Williams, Ph.D., a postdoctoral fellow in the Hangauer lab. ‘By targeting these early regrowth mechanisms, we could help patients stay in remission longer and reduce the risk of recurrence.’
But here’s the controversial question: If cancer cells are exploiting a natural cell death process to survive, should we rethink how we approach treatment altogether? Could this discovery lead to therapies that work in harmony with the body’s own mechanisms rather than against them? Weigh in below—do you think this research could revolutionize cancer care, or are we still missing a crucial piece of the puzzle?
Funded by the Department of Defense, the National Institutes of Health, and the American Cancer Society, this study not only sheds light on a previously unknown survival tactic of cancer but also offers hope for more effective treatments. Hangauer, a cofounder and consultant for BridgeBio subsidiary Ferro Therapeutics, emphasizes the potential of combination therapies targeting DFFB to extend treatment responses.
Stay ahead of the curve and keep up with groundbreaking discoveries like this. Subscribe to the UC San Diego newsletter today and be part of the conversation shaping the future of cancer research.
